With advancements in technology growing exponentially, the bio-pharmaceutical scene is constantly changing. Don’t worry, analyst Ian Somaiya keeps track of the major shifts in the bio-pharm sector and has done his financial research. Recommendations about companies such as, Gilead Sciences (GILD), Incyte Corporation (INCY) and Neurocrine (NBIX), have earned Ian the number 209 spot of out 2362 analysts and a 4.0% average return over S&P-500.
Ian’s positive returns helped earn him a 60% success rate of recommendations, including his advice to BUY Incyte Corp (INCY). Ian recommended BUY INCY following his observation that, “positive Phase II data in pancreatic cancer last year was just the beginning.” Now, “Our note this morning provides strong evidence for a much larger role of CRP across solid tumors and supports INCY’s decision to evaluate ‘093 (P13K inh) + ‘110 (Jak 1inh) in diffuse large B cell lymphoma (DLBCL), an incremental $3bn opportunity.” Ian just issued this recommendation in mid-January and already he has earned +1.9% over S&P-500.
Ian also recommended BUY Gilead Sciences (GILD) with a $118 price target and naming the stock the “best top stock pick for 2014”. Ian expects Gilead to continue to dominate, as was the case in the Hepatitis C market. “HIV is Gilead’s biggest franchise and we expect it to continue to grow. We believe their oncology pipeline is a free call option, as our estimates for Idelalisib (for chronic lymphocytic leukemia and non-Hodgkin’s lymphoma) are below consensus and we and the Street ignore momelotenib altogether; a $2bn+ opportunity.” Ian has earned +12.2% with this recommendation.
And Ian’s most successful recommendation of the year has earned him +17.6% over S&P-500. Ian recommended BUY Incyte (INCY) while using 2013 results as his jumping off point, “While 2013 was a year of positive surprises for a previously under-appreciated pipeline, we expect the pipeline to exceed heightened expectations in 2014.” Ian added, “we believe the US market opportunity of $300mn in pancreatic cancer would rise to $2.1bn with the inclusion of just the refractory setting of these additional cancer indications.”
Of course, not all of Ian’s recommendations have been successful. Ian recommended BUY Celgene (CELG) with a price target of $236. The company focuses on developing therapeutic drugs for hematological malignancies and autoimmune diseases, and Ian was very confident in one of the company’s drugs. “We believe Celgene’s blockbuster drug, Revlimid for multiple myeloma (MM), is less than a third of the way to realizing its peak sales potential.” Ian sees a $6-8 billion opportunity, but right now Ian has lost -1.2% over S&P-500.
The cures of tomorrow are in drug trials today. So, to keep track of Ian’s recommendations as the bio-pharm scene fluctuates, along with other analyst recommendations, download TipRanks, and start making financial decisions with advice you can trust.
